| WHITEHAWK THERAPEUTICS |
| USA |
| Gesundheit |
| US00032Q1040 / A3CSR9 |
| 3350 (Frankfurt) / WHWK (NASDAQ) |
| FRA:3350, ETR:3350, 3350:GR, NASDAQ:WHWK |
| - |
| https://ir.whitehawktx.co.. |
|
Whitehawk Therapeutics, Inc. is an oncology biotechnology company focused on the discovery and development of antibody-drug conjugate (ADC) therapies for cancer. The company’s primary objective is to leverage next-generation ADC platform technologi..
>Volltext.. |
| 160.06 Mio. EUR |
| 53.18 Mio. EUR |
| - |
| -104.49 Mio. EUR |
| -98.64 Mio. EUR |
| -1.43 EUR |
| - |
| 29.63 Mio. EUR |
| - |
| 11.13 |
| -100% |
| -492.69% |
| - |
| - |
| - |
| WHITEHAWK THERAPEUTICS, WHITEHAWK THERAPEUTIC, AADI BIOSCIENCES |
| 13.05.26 |
|
||||
|